// App-Quantinova.ai

1145 : Rivaroxaban Versus Enoxaparin For Prevention Of Venous Thromboembolism In Elective Total Hip Replacement: A Retrospective Cohort Study

Researchers

Presenter

  • Stephanie W Young

Principal Investigators

  • Pharm.D

  • Tiffany Lee

  • John Hawboldt

  • Laurie Twells

  • Jason Kielly

  • Maria Mathews

  • Andrew Furey

  • Kuljit Grewal

  • Lisa D Bishop

  • Carla Dillon

Medical Centers

  • Division of Community Health & Humanities, Memorial University, St. John's, NF, Canada

  • School of Pharmacy, Memorial University, St John's, NF, Canada

  • Discipline of Surgery, Faculty of Medicine, Memorial University, St. John's, NF, Canada

  • Division of Medicine Hematology, Eastern Health, St. John's, NF, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • Body mass index

Drug/Treatment

  • rivaroxaban

  • Enoxaparin

  • Enoxaparin sodium

  • Heparin

Outcome

  • N/A

Study Design

  • superiority

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved